Patient-Reported Well-Being in Value-Based Routine Care Using Tildrakizumab: 52-week Interim Data of the Phase IV Positive Study

Patient-Reported Well-Being in Value-Based Routine Care Using Tildrakizumab: 52-week Interim Data of the Phase IV Positive Study

Ulrich Mrowietz,1 Rachel Sommer,2 Sascha Gerdes,1 Ziad Reguiai,3 Wolfgang Weger,4 Esteban Daudén,5 Julia-Tatjana Maul,6,7 Pierre-Dominique Ghislain,8 Philip M Laws,9 Luigi Naldi,10 Elke De Jong,11 Sicily Mburu,12 Volker Koscielny,13 Eric Massana,13 Arnau Domenech,13 Kristian Gaarn du Jardin,13 Ismai...

Full description

Saved in:
Bibliographic Details
Main Authors: Mrowietz U, Sommer R, Gerdes S, Reguiai Z, Weger W, Daudén E, Maul JT, Ghislain PD, Laws PM, Naldi L, De Jong E, Mburu S, Koscielny V, Massana E, Domenech A, Gaarn du Jardin K, Kasujee I, Augustin M
Format: Article
Language:English
Published: Dove Medical Press 2025-06-01
Series:Psoriasis: Targets and Therapy
Subjects:
effectiveness
psoriasis
real-world evidence (RWE)
tildrakizumab
well-being
WHO-5 Well-being Index.
Online Access:https://www.dovepress.com/patient-reported-well-being-in-value-based-routine-care-using-tildraki-peer-reviewed-fulltext-article-PTT
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.dovepress.com/patient-reported-well-being-in-value-based-routine-care-using-tildraki-peer-reviewed-fulltext-article-PTT

Similar Items